Related Experiment Video
Updated: Mar 14, 2026

Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
"How I manage" IgG4-Related Disease
Emanuel Della-Torre1, John H Stone2,3
1Unit of Medicine and Clinical Immunology, IRCCS San Raffaele Scientific Institute, Università Vita-Salute San Raffaele, Milan, Italy.
IgG4-related disease (IgG4-RD) is an immune-mediated disease driven by interactions on several levels between cells of the B and T lineages. A key driver of IgG4-RD is believed to be a novel CD4+ cytotoxic T lymphocyte that bears SLAM-F7 on its surface. This cell is presumed to be sustained by continuous antigen presentation by cells of the B cell lineage, particularly plasmablasts. Because IgG4-RD has been recognized for fewer than 15 years as a unified diagnostic entity, no controlled clinical trials or few prospective studies of any sort have been performed. Although progress in understanding disease pathophysiology will likely lead in due course to disease-specific therapies-undoubtedly with implications for other immune-mediated diseases-at this juncture, the management of IgG4-RD remains more an art than a science, driven largely by the published clinical experience of only a few centers of expertise. We identify here six common management dilemmas in IgG4-RD and describe our typical approach to the management of each one.
IgG4-related disease (IgG4-RD) is an immune-mediated disease driven by interactions on several levels between cells of the B and T lineages. A key driver of IgG4-RD is believed to be a novel CD4+ cytotoxic T lymphocyte that bears SLAM-F7 on its surface. This cell is presumed to be sustained by continuous antigen presentation by cells of the B cell lineage, particularly plasmablasts. Because IgG4-RD has been recognized for fewer than 15 years as a unified diagnostic entity, no controlled clinical trials or few prospective studies of any sort have been performed. Although progress in understanding disease pathophysiology will likely lead in due course to disease-specific therapies-undoubtedly with implications for other immune-mediated diseases-at this juncture, the management of IgG4-RD remains more an art than a science, driven largely by the published clinical experience of only a few centers of expertise. We identify here six common management dilemmas in IgG4-RD and describe our typical approach to the management of each one.
More Related Videos
14:18Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
Published on: October 13, 2023
06:35An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Related Concept Videos
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Irritable Bowel Syndrome III: Medical and Nursing Management